Literature DB >> 24496328

M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.

Olga V Leontieva1, Mikhail V Blagosklonny1.   

Abstract

A groundbreaking publication by Sinclair and coworkers has illuminated the pseudo-hypoxic state in aging and its reversibility. Remarkably, these data also fit the mTOR-centered model of aging. Here we discuss that the mTOR pathway can cause cellular pseudo-hypoxic state, manifested by HIF-1 expression and lactate production under normoxia. We found that rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro. This reduction was independent from mitochondrial respiration: rapamycin decreased lactate production in normoxia, hypoxia, and in the presence of the OXPHOS inhibitor oligomycin. We suggest that pseudo-hypoxic state is not necessarily caused by mitochondrial dysfunction, but instead mitochondrial dysfunction may be secondary to mTOR-driven hyperfunctions. Clinical applications of rapamycin for reversing pseudo-hypoxic state and lactate acidosis are discussed.

Entities:  

Keywords:  HIF-1; NAD; hypoxia; mTOR; mitochondria; oxidative phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24496328     DOI: 10.4161/cc.27973

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  32 in total

1.  Fasting levels of hepatic p-S6 are increased in old mice.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 2.  Geroconversion: irreversible step to cellular senescence.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress.

Authors:  M-G Ryou; G R Choudhury; W Li; A Winters; F Yuan; R Liu; S-H Yang
Journal:  Neuroscience       Date:  2015-06-03       Impact factor: 3.590

4.  Human Periosteal Derived Stem Cell Potential: The Impact of age.

Authors:  Concetta Ferretti; Guendalina Lucarini; Chiara Andreoni; Eleonora Salvolini; Novella Bianchi; Giovanni Vozzi; Antonio Gigante; Monica Mattioli-Belmonte
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

5.  Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

Authors:  Rafaela Andrade-Vieira; Donna Goguen; Heidi A Bentley; Chris V Bowen; Paola A Marignani
Journal:  Oncotarget       Date:  2014-12-30

6.  By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.

Authors:  Weiqi Dai; Fan Wang; Jie Lu; Yujing Xia; Lei He; Kan Chen; Jingjing Li; Sainan Li; Tong Liu; Yuanyuan Zheng; Jianrong Wang; Wenxia Lu; Yuqing Zhou; Qin Yin; Huerxidan Abudumijiti; Rongxia Chen; Rong Zhang; Li Zhou; Zheng Zhou; Rong Zhu; Jing Yang; Chengfen Wang; Huawei Zhang; Yingqun Zhou; Ling Xu; Chuanyong Guo
Journal:  Oncotarget       Date:  2015-05-30

7.  Lactate promotes PGE2 synthesis and gluconeogenesis in monocytes to benefit the growth of inflammation-associated colorectal tumor.

Authors:  Libin Wei; Yuxin Zhou; Jing Yao; Chen Qiao; Ting Ni; Ruichen Guo; Qinglong Guo; Na Lu
Journal:  Oncotarget       Date:  2015-06-30

8.  PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.

Authors:  Lan Yu; Zeng-Fu Shang; Jian Wang; Hongtao Wang; Fang Huang; Zhe Zhang; Ying Wang; Jianguang Zhou; Shanhu Li
Journal:  Oncotarget       Date:  2015-08-21

Review 9.  Koschei the immortal and anti-aging drugs.

Authors:  M V Blagosklonny
Journal:  Cell Death Dis       Date:  2014-12-04       Impact factor: 8.469

10.  JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Authors:  Haifeng Qiu; Amanda L Jackson; Joshua E Kilgore; Yan Zhong; Leo Li-Ying Chan; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.